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Abstract
The aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor that mediates the
biological and toxic effects of a wide variety of structurally diverse chemicals, including the toxic
environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). While significant
interspecies differences in AHR ligand binding specificity, selectivity and response have been
observed, the structural determinants responsible have not been determined and homology models
of the AHR ligand-binding domain (LBD) are available for only a few species. Here we describe
the development and comparative analysis of homology models of the LBD of sixteen AHRs from
twelve mammalian and nonmammalian species and identify the specific residues contained within
their ligand binding cavities. The ligand-binding cavity of the fish AHR exhibits differences from
mammalian and avian AHRs, suggesting a slightly different TCDD binding mode. Comparison of
the internal cavity in the LBD model of zebrafish (zf) AHR2, which binds TCDD with high
affinity, to that of zfAHR1a, which does not bind TCDD, revealed that the latter has a
dramatically shortened binding cavity due to the side chains of three residues (Tyr296, Thr386,
His388) that reduce the internal space available to TCDD. Mutagenesis of two of these residues in
zfAhR1a to those present in zfAHR2 (Y296H, T386A) restored the ability of zfAHR1a to bind
TCDD and to exhibit TCDD-dependent binding to DNA. These results demonstrate the
importance of these two amino acids and highlight the predictive potential of comparative analysis
of homology models from diverse species. The availability of these AHR LBD homology models
will facilitate in depth comparative studies of AHR ligand binding and ligand-dependent AHR
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activation and provide a novel avenue to examine species specific differences in AHR
responsiveness.
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INTRODUCTION
The aryl hydrocarbon receptor (AHR) is a ligand-dependent basic helix-loop-helix (bHLH)/
Per-ARNT-Sim (PAS) domain-containing transcription factor that regulates gene expression
and other cellular signaling events (1-3). Mechanistically, binding of ligand to the AHR in
the cytosol of a cell stimulates translocation of the AHR protein complex into the nucleus
and its subsequent dimerization with the ARNT (AHR nuclear translocator) protein
transforms the ligand:AHR:ARNT complex into its high-affinity DNA binding form (3-5).
Binding of the ligand-activated AHR complex to its specific DNA recognition site, the
dioxin responsive element (DRE), stimulates transcription of adjacent genes and thus
mediates the toxic and biological effects of AHR ligands (1,3).
Unlike many nuclear receptors, the AHR can bind and be activated by a wide variety of
structurally diverse natural and synthetic compounds (6-9), including halogenated aromatic
hydrocarbons (HAHs) such 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin), and the
spectrum of biological and toxic effects produced by the ligand-activated AHRs is
dependent upon the physicochemical characteristics and metabolic persistence of the ligand
(3,7,10). More recent studies have reported that the ligand binding promiscuity of a given
AHR may result from differential binding of structurally diverse ligands within the AHR
ligand-binding cavity (11-14), similar to the mechanisms responsible for pregnane X
receptor ligand binding promiscuity (15,16).
While the lack of any three-dimensional structure information on the AHR ligand binding
domain (LBD) has prevented detailed molecular analysis of the mechanisms of AHR ligand
binding, we and others have used the availability of crystal and nuclear magnetic resonance
(NMR) structures of homologous protein domains to develop homology models of the AHR
LBD for such analysis (12,17-20). These theoretical models not only have revealed key
structural aspects of the domain, but when coupled with site directed mutagenesis and
functional analysis, have proven to be helpful in identifying amino acids important in ligand
binding and ligand-dependent AHR activation (12,17-19,21). More recently, these models
have been used in molecular docking studies in an attempt to elucidate the detailed
interactions of some known ligands (agonists) within the AHR LBD as well as in the virtual
screening of collections of putative ligands (12,18-20,22-25). While the binding modes of
TCDD and other ligands within the AHR LBD of a given species (typically that of mouse or
human AHR) have been predicted by these approaches, experimental confirmation of these
proposed interactions are generally lacking. Moreover, until recently, modeling studies have
been focused on a limited number of species (12,17-20). The availability of homology
models for AHR LBD from a wide variety of species would not only provide avenues to
further investigate basic mechanisms of ligand binding and AHR activation, but also to
examine mechanisms and structural determinants responsible for the dramatic intra- and
inter-species differences that have been observed in AhR ligand binding, ligand selectivity
and response (3,10,14,26,27).
Accordingly, here we describe the development and comparative analysis of homology
models of the LBD of sixteen AHRs from twelve mammalian and non-mammalian species.
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By comparing the volume and shape of the binding cavities in different AHRs, as well as the
physicochemical properties of the internal residues, we inferred the role of amino acids that
are known to affect TCDD binding affinity. To further assess the value of this approach to
predict structure-function relationships, we focused on experimental verification of residues
predicted to be important in determining the functional attributes of a fish AhR. Zebrafish
(Danio rerio) possess three AHRs, one of which (AHR1a) has been shown previously to lack
the ability to bind TCDD and DNA and to activate transcription in the presence of TCDD
[28,29]. Structural modeling of representative fish AHRs was used to guide site-directed
mutagenesis and functional analysis in identifying the specific residues within the zebrafish
AHR1a LBD that contribute to its inability to bind TCDD or exhibit TCDD-dependent DNA
binding activity. On this basis, zfAHR1a mutants designed to restore TCDD-responsiveness
were prepared and experimentally validated, demonstrating the key role of these residues
and highlighting the predictive value of the comparative modeling analysis. The proposed
approach will not only further contribute to elucidating the mechanisms of AHR ligand
binding, but it will provide additional insights into the diversity of AHR ligands and the
species-specific differences in AHR responsiveness.
EXPERIMENTAL PROCEDURES
Homology Modeling
The PASB ligand binding domain (LBD) structures of sixteen mammalian, avian and fish
AHRs (Table 1) were generated by homology modeling following our previously described
protocol (17,18). Briefly, template identification by sequence similarity was performed
independently for each target sequence using PSI-BLAST (30) against the Protein Data
Bank (31) with default parameters. For all targets, the top hits were the PASB domains of
hypoxia-inducible factor 2α (HIF-2α) and ARNT. NMR structures of HIF-2α [PDB ID
1P97 (32)] and ARNT [PDB ID 1X00 (33)] were chosen and the most representative
structure in the NMR ensemble of each template was selected using NMRCLUST (34). The
two templates were structurally aligned with DALI-Lite (35,36). For each AHR, the target±
template sequence alignment was generated with CLUSTALW (37,38) and the result was
confirmed using the Align-2D command within MODELLER (39-41). Models of each AHR
LBD were built with MODELLER version 8v1 (39-41), a program that implements
comparative modeling by satisfying spatial restraints. One hundred candidate models were
derived for each target and the optimal model selected was that with the lowest value of the
objective function. The quality of the obtained models was assessed by the PROCHECK
program (42), which provides information about the stereo-chemical quality, and by the
ProSA validation method (43,44), which evaluates model accuracy and statistical
significance with a knowledge-based potential. Secondary structures were attributed by
DSSPcont (45). This program extends the discrete assignments of secondary structure
performed by DSSP (46) to a continuous assignment in the same categories providing
increased accuracy. The continuum results are calculated by weighted averages over 10
discrete DSSP assignments with different hydrogen bond thresholds. Three-dimensional
visualization and images of the resulting AHR LBD structures were generated using
PyMOL (47).
Analysis of Structural Cavities
Identification and characterization of surface pockets and internal cavities in each of the
modeled structures were performed with the CASTp server (48). This program allows
identification and calculation of the Connolly©s molecular surface and volume for all pockets
and cavities in a protein structure. It ranks the cavities by size, where the largest one is
usually the binding site. The representations of the resulting cavity surfaces were produced
with PyMOL (47).
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Chemicals
[3H]TCDD (>99% radiochemical purity) was obtained from Chemsyn Science Laboratories
(Lenexa, Kansas, USA) or was a kind gift from Dr. Steve Safe (Texas A&M University).
[35S]Methionine was purchased from Amersham (Piscataway, New Jersey, USA) or Perkin
Elmer (Waltham, MA) and [32P]γATP was from Perkin Elmer.
Plasmids
The zebrafish AHR1b (zfAHR1b) expression construct pcDNA-zfAHR1b was described
previously (29). Expression constructs for zebrafish AHR1a, AHR2, ARNT2b, and
ARNT1c (pBKCMV-zfAHR1a, pBKCMV-zfAHR2, pBKCMV-zfARNT2b, and pBKCMV-
zfARNT1c, respectively) [28,49-50] were generously provided by Dr. R. Tanguay (Oregon
State University, Corvallis, OR, U.S.A.) and Dr. R. E. Peterson (University of Wisconsin,
Madison, WI, U.S.A.). In the course of sequencing the pBKCMV-zfAHR1a plasmid, seven
single-nucleotide differences in the zfAHR1a cDNA sequence from that of the GenBank
zfAHR1a sequence were identified, including two non-synonymous differences resulting in
L129I and P280T substitutions in the zfAHR1a protein.
zfAHR1a site-directed mutagenesis, in-vitro protein synthesis and functional analysis
Three amino acid residues (296, 386, and 388) in the ligand-binding domain of zfAHR1a
were mutated using the Quick-change XL site-directed mutagenesis kit (Stratagene),
following the manufacturers instructions. The pBKCMV-zfAHR1a plasmid was amplified
with Pfu polymerase; the complementary primer pairs used for each mutated site are
included in the supplemental information (Supplemental Table S1). The primer pair
zf1-3868/zf1-c3868 was used to generate a double mutant zfAHR1a at residues 386 and
388. A splicing approach was used to generate the double mutations at positions 296/386
and 296/388, and the triple mutation at 296/386/388. The AgeI/EcoRI fragment containing
amino acid residues 350-805 was excised from the Y296H mutant and replaced with the
corresponding fragment from each of the other zfAHR1a mutants (386, 388, and 386/388).
All mutant zfAHR1a constructs were fully sequenced.
Zebrafish AHR and ARNT proteins were expressed in vitro using the T3-coupled (for
pBKCMV constructs) or T7-coupled (for pcDNA3.1 constructs) TNT-Quick Coupled
Reticulocyte Lysate Systems (Promega) following the manufacturer©s recommendations.
AHR ligand-binding was determined using unlabeled proteins by velocity sedimentation
(sucrose gradient centrifugation) analysis in a vertical tube rotor as described previously
(51). The TNT reactions were incubated overnight at 4C with 8 nM [ 3H]TCDD;
nonspecific binding was determined using reactions containing an empty vector
(unprogrammed lysate) (51).
For DNA binding analysis, aliquots (1.5 μl) of the indicated in vitro expressed wild-type or
mutant AHR and ARNT were combined with 7 μl of MEDG (25 mM MOPS-NaOH pH 7.5,
1 mM EDTA, 1 mM DTT, 10% glycerol) or MEDGK (MEDG supplemented 150 mM KCl)
buffer and incubated in the presence of 20 nM TCDD or other compound [or 1% (v/v)
DMSO] for 1.5-2 h at room temperature. For zfAHRs, DNA binding analysis was carried
out using zfARNT1c because preliminary analyses revealed that it resulted in a greater
amount of TCDD-dependent DNA binding than that obtained using zfARNT2b (data not
shown). Mouse DRE3-containing oligonucleotide was labeled with [32P]-ATP (Perkin
Elmer) and DNA binding (gel retardation) analysis carried out as previously described (52),
except that the amount of KCl in the DNA binding incubation was adjusted to a final
concentration of 200 mM. DRE bound complexes were separated in native polyacrylamide
gels and constitutive and inducible protein-DNA complexes in the dried gel were quantitated
using a Fujifilm FLA9000 imager with Multi Gauge software. For protein expression
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analysis, zebrafish AHR and ARNT constructs were expressed using TNT system in the
presence of [35S]-methionine and aliquots subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis, followed by fluorography. The amount of radioactivity
contained in the bands was either determined by liquid scintillation counting of the excised
bands or by imaging analysis using a Fujifilm FLA9000 with Multi Gauge software.
Transient transfection studies in COS-7 cells were carried out to analyze ligand-dependent
transcriptional activation by the wild-type and mutant zfAHRs. COS-7 cells were obtained
from the American Type Culture Collection (Manassas, VA) and maintained in DMEM
(Sigma, St. Louis, MO) supplemented with fetal calf serum (10% final concentration) at
37C under 5% CO 2. Cells were plated at 5  10 4 cells/well in 48-well plates and
transfections were carried out in triplicate wells 24 hours after plating. DNA and
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) each were diluted in serum-free
DMEM and a total of approximately 300 ng of DNA was complexed with 1 μl of
Lipofectamine 2000. The mixture was then added to cells in DMEM with serum. Cells were
dosed 5 hours after transfection with either DMSO or TCDD (10 nM final concentration) at
0.5% final DMSO concentration. Renilla luciferase (pGL4.74, Promega, Madison, WI) was
used as the transfection control. Transfected DNA amounts were 5 ng each of the AHR
expression constructs, 25 ng of ARNT2b, 20 ng of pGudLuc6.1, and 3 ng of pGL4.74. The
total amount of transfected DNA was kept constant by addition of pcDNA3.1 vector with no
insert. Cells were lysed 18 hours after dosing and luminescence was measured using the
Dual Luciferase Assay kit (Promega, Madison, WI) in a TD 20/20 Luminometer (Turner
Designs, Sunnyvale, CA). The final luminescence values were expressed as a ratio of the
firefly luciferase units to the Renilla luciferase units.
RESULTS AND DISCUSSION
Selection of AHR sequences
Sixteen AHRs (from twelve different species) with known TCDD binding affinity (Kd) data
were selected for the generation of the PASB LBD homology models with the goal of
comparative analysis of their structural and chemical characteristics and ligand binding
cavities. The names, accession numbers and relative TCDD binding affinity classification of
the various AHRs used in this analysis are presented in Table 1. Among these AHRs, the
C57BL/6 mouse mAHR has been commonly used as the reference AHR for comparison
purposes in many studies reporting AHR affinity values from one or several species. The use
of a reference AHR in affinity measurements was necessary for these studies since the
resulting values usually vary depending on the experimental system, experimental
conditions and the ligand binding protocol. Accordingly, TCDD binding affinity estimates
for the C57BL/6 mAHR, which is used as the basis for comparisons, are reported to range
between 6 pM ± 2.4 nM; this is considered to be high affinity (53-58).
Those AHRs with an affinity for TCDD equal to or greater than that of the C57BL/6 mAHR
were classified as having `high' TCDD binding affinity; these included rat, hamster, rabbit,
guinea pig, beluga whale, harbor seal and chicken AHRs (Table 1). Those AHRs with
TCDD binding affinity that was consistently 3- to 10-fold lower than that of C57BL6
mAHR were designated as having `medium' binding affinity AHRs (Table 1) and included
DBA mice and human AHRs (53,55,58,59). The tern AHR also demonstrated an
approximately 4- to 6-fold lower TCDD binding affinity than that of high affinity mAHR
and chicken AHR, but since [3H]TCDD binding to this AHR was particularly sensitive to
washes with detergent-containing buffer (54), it was classified as a `medium/low' affinity
AHR (Table 1).
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Molecular analysis of several fish species revealed that many contain multiple distinct AHR
genes and gene products that vary in their affinity for TCDD (60). For example, killifish
contain at least two distinct AHRs, with kfAHR1a having low affinity for TCDD (61) and
kfAHR2a having medium TCDD affinity (unpublished results). In contrast, the zebrafish
contains three distinct AHRs (zfAHR1a, zfAHR1b and zfAHR2 (28,29,49)). While zfAHR2
has a high affinity for TCDD (Kd ~1 nM), that for zfAHR1b is lower, although it could not
be quantitatively determined due to experimental limitations (29). However, based on the
approximately 8-fold lower potency of TCDD-dependent activation of transcription in
COS-7 cells transiently transfected with zfAHR1b, compared to those containing zfAHR2,
zfAHR1b is designated as having a `medium' TCDD-binding affinity (29). Interestingly, in
contrast to zfAHR2 and zfAHR1b, zfAHR1a did not demonstrate any detectable [3H]TCDD
binding nor transcriptional response to TCDD (28,29).
Homology models and binding cavities
Structural models of the AHR LBDs of the first seven mammalian AHRs in Table 1 were
previously obtained by homology modeling (17,18) and structure prediction of the
remaining nine sequences was performed as previously described (18). A multiple sequence
alignment of the modeled regions (107 residues corresponding to the 278-384 region of
mAHR) is presented in Supplemental Figure S1. The HIF-2α and ARNT structures were
used as templates because these were the PAS domains with the highest degree of sequence
identity with the AHR PAS B (HIF-2α in the range 25-30% and ARNT of about 20%, in the
aligned regions) available. For each target sequence, the model with the lowest value of the
MODELLER objective function was selected for the subsequent analysis. PROCHECK
validation indicated a good stereochemical quality for all the models, with 85 - 94% of
residues belonging to the most favored areas of the Ramachandran plot and the overall G-
factors ranging from -0.15 to -0.05 (this index ranges from -0.5 to 0.3 for structures solved
at 1.5  resolution). Moreover the ProSA z-scores were between -3.29 and -5.25, within the
range of values for native protein structures of similar size.
A first comparison of the structural characteristics of the whole set of models indicated that
the overall fold was well conserved, as shown in the upper part of Figure 1 by the
representative models of mAHR, chAHR and zfAHR2 and, in more detail, in Supplemental
Figure S2 by the superimposition of the main-chain of the sixteen models. Small variability
is observed only in the loops encompassing a residue insertion (DE loop) and a two-residue
deletion (HI loop) of the global alignment with the templates (17). The high structural
conservation among the AHR models was also confirmed by the low values of root mean
square distance (RMSD) between each model and the reference mAHR model (less than 1 
on the Cα atoms). Moreover, the secondary structure attribution was highly consistent, with
slight differences only in some connecting loops (see the representative models in Figure 1
and secondary structure attribution for all models in Supplemental Figure S1).
The analysis of structural pockets and cavities, performed by the CASTp server indicates the
presence of a buried cavity in the core of each modeled domain. These cavities have internal
volumes ranging from 300 - 600  3, which is within the range (100 - 800  3) commonly
observed in protein binding pockets or cavities (62). Given the somewhat inaccurate
assignment of internal side chain conformations associated with the homology modeling
procedure, the volume of a given cavity alone cannot be used reliably to predict ligand
accessibility. However, the analysis of internal side chains lining the cavity (obtained from
the CASTp analysis) can provide insights into their possible steric and physico-chemical
interactions with the bound ligand. This analysis helps to understand the role of amino acids
at key positions that were previously demonstrated to affect TCDD binding affinity in the
mammalian and avian LBDs (53,54,58), as well as to make hypotheses on their role in the
fish LBDs.
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One avenue to inter-species analysis of LBD properties is comparison of the cavities of the
highest affinity receptors in each class. For the mammalian AHRs with relatively high
affinity for TCDD (first seven AHRs in Table 1) a ªconsensus cavityº was previously
defined as the cavity delimited by the internal residues (obtained by CASTp) that are
conserved in all the modeled LBDs (18). This can be viewed as the internal space shared by
all these domains, and as such it represents the internal space required for optimal TCDD
binding to mammalian AHRs. The cavities of the chAHR and the zfAHR2, both with high
affinity for TCDD (Table 1), were taken as reference cavities for avian and fish AHRs. The
molecular surfaces that include the selected cavities are shown in Figure 1 (lower panel).
The consensus cavity for the high affinity mammalian and the chAHR cavity are very
similar in shape and size and, as described below, they also share the same internal
conserved residues (see Figure 2A). In contrast, the cavity of the high affinity fish AHR is
characterized by a higher number of internal residues (see Figure 3A), associated with a
more elongated shape at both sides (delimited by the Fα helix on one side and the C-
terminal β-strands on the other). These distinct characteristics suggest a slightly different
TCDD binding mode for fish AHRs.
Mammalian and avian AHR LBD models
In high affinity mammalian AHRs, seven internal residues have been shown to constitute the
ªTCDD-binding fingerprintº (i.e. the residues identified by site-directed mutagenesis and
functional analysis of the mAHR LBD as necessary for optimal TCDD binding (18; Figure
2B and 2C). Of these, Ala375 in the C57BL6 mAHR has been demonstrated to be essential
for optimal TCDD binding, since its mutation to valine (17,63) or natural occurrence as
valine in the DBA mouse AHR or in the human AHR (V381) (53,58) results in a decreased
affinity for TCDD. The position of this amino acid relative to the other fingerprint residues
within the internal cavity is illustrated in Figure 2B. When this amino acid is mutated to Val,
it introduces steric hindrance at this end of the modeled cavity (Figure 2C), effectively
decreasing the cavity volume and potentially affecting ligand interactions with other
fingerprint residues (17,18). Thus, a decrease in the internal cavity volume (below that of the
consensus cavity) appears to correlate with the decreased TCDD binding affinity observed
with AHRs containing other amino acids at position 375 (17,63).
For avian AHRs, the internal residues of the chAHR and tAHR LBD are shown in Figure
2A. Previously, the difference in TCDD binding affinity between the chAHR (high affinity
for TCDD) and tAHR (medium/low affinity for TCDD) was attributed to two amino acid
substitutions, I324/V325 and S380/A381 (54). Both these substitutions involve residues that
are internal to the modeled cavities and that belong to the ªTCDD-binding fingerprintº for
mammalian AHRs (18). Since neither of these substitutions significantly changes the shape
and size of the internal cavity in the modeled LBD structures (Figure 2D), it is conceivable
that TCDD binding in the chAHR LBD may be stabilized by specific interactions with
amino acids in or adjacent to these positions. Accordingly, hydrophobic stabilization by the
long Ile319 side chain (corresponding to position 324/325 in the ch/tAHR) has been
previously suggested to be necessary for optimal TCDD binding by mAHR (18). Therefore,
Ile324 in the chicken AHR LBD may stabilize bound TCDD to a higher extent than Val325
present in the tAHR LBD. The role of chicken Ser380 is less clear, since both the high
affinity mAHR and the medium/low affinity tAHR have Ala at this position (54). It is
possible that optimal electrostatic interactions with the TCDD molecule needed for high
affinity binding require the presence of a polar residue, like Ser, in the region defined by the
faced residue pair Ser359-Ala375, in mAHR, or Ala364-Ser380 in chAHR. Binding with the
tAHR (Ala365-Ala381) lacks this stabilizing effect (Figure 2D). Further studies will be
required to understand the underlying mechanism of the A381S-dependent stabilization of
TCDD binding to the tAHR. Nevertheless, these modeling results demonstrate that residues
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shown to be critical for binding play evolutionarily conserved roles as part of the ligand-
binding cavities of AHRs in mammals and birds.
Fish AHR LBD models
The above analyses and previous mutagenesis results (17,18) help to elucidate the
importance that the internal cavity size and/or specific amino acid interactions may have in
determining TCDD binding affinity. Three zebrafish AHRs have been described (zAHR1a,
zfAHR1b and zfAHR2) and while zfAHR2 and zfAHR1b can bind TCDD with high and
medium affinity, respectively, zfAHR1a fails to bind TCDD (28,29). As expected, TCDD
can stimulate gene expression by zfAHR2 and zfAHR1b, but not by zfAHR1a (28,29). A
previous homology modeling study suggested that the inability of zfAHR1a to bind TCDD
was due to the presence of different internal cavity residues from those in zfAHR2 that
decreased the volume and altered the polarity of the binding pocket itself (20).
Comparison of the internal residues in the zfAHR2 and zfAHR1b modeled cavities (Figures
3A, B, C) indicates that, while most of these residues occupy corresponding positions and
are conserved in the two AHRs, a small group lies in different positions. These variations
result in differences in the size and shape of the two cavities and, in particular, a slightly
reduced space available for the ligand in the zfAHR1b. This steric characteristic is also
observed in the modeled cavities of the other two fish AHRs with low or medium TCDD
binding affinity, kfAHR1a and kfAHR2a, and it may explain the reduced binding of these
AHRs with respect to the zfAHR2.
Comparison of the LBD of the high affinity binding zfAHR2 to that of zfAHR1a, which
does not bind TCDD (28,29), revealed a number of different residues, but only four amino
acid differences were identified among the internal residues of these LBDs (Figure 3A, D,
E). These amino acid differences (H296Y, N341G, A386T and Q388H) result in a
dramatically shortened internal cavity in the zfAHR1a model (Figure 3D, E), as a
consequence of the high steric hindrance of the side chains of three of the residues in
zfAHR1a (Tyr296, Thr386, His388) that causes a break in the internal space available to
TCDD, limiting its access to the binding cavity. This was also confirmed by the smaller
calculated volume (about 300  3) and truncated shape of this cavity determined by CASTp
in comparison to the internal cavity in zfAHR2 (about 600  3) which spans the entire
domain fold (Figure 3B). Moreover, the presence of different inter-residue interactions in
the central part of the cavity may further limit the access of ligand as the Tyr296, Thr386,
His388 residues would create a different electrostatic field, and the two facing hydroxyl
groups of Tyr296 and Thr386 may generate a network of hydrogen bonds among the side
chains.
zfAHR1a LBD mutagenesis and functional analysis
While our analysis and those of Bisson et al. (20) suggest that the steric and electrostatic
effects from the side chains of Tyr296, Thr386 and His388 are responsible for the loss of
TCDD binding to zfAHR1a, this has not been confirmed experimentally. Accordingly, to
test this hypothesis and more generally to evaluate the ability of homology modeling to
predict AHR structure-function relationships, individual and multiple mutations (Y296H,
T386A and/or H388Q) were introduced into zfAHR1a and the ligand (TCDD) binding and
ligand-dependent transformation and DNA binding of the mutant AHRs were determined.
These specific amino acid substitutions change the specific zfAHR1a residues into those
present in zfAHR2 and, based on our homology model, are expected to increase the internal
cavity volume and restore the electrostatic environment of the LBD.
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Ligand ([3H]TCDD) specific binding to wild-type and mutant in vitro synthesized zfAHR1a
proteins was performed using sucrose density centrifugation. The specific mutations did not
affect the level of protein synthesized in vitro from these mutant zfAHR constructs
(Supplemental Figure S3). The results of the ligand binding analyses reveal that two of the
single mutations, Y296H and T386A, resulted in partial restoration of specific [3H]TCDD
binding to the zfAHR1a (Figure 4). Interestingly, [3H]TCDD specific binding to zfAHR1a
containing the Y296H+T386A double mutation was not only completely restored, but the
amount of binding was 2- to 3-times greater than that observed for the fully functional
zfAHR1b or zfAHR2. No increase in [3H]TCDD specific binding was observed with the
H388Q mutation and inclusion of this mutation had a negative effect on ligand binding
restoration when combined with a T386A mutation, but no effect on AHRs containing the
Y296H mutation (Figure 4). While the underlying mechanism of the increased ligand
binding of zfAHR1a containing the Y296H+T386A mutation is unclear, it is possible that
the enhanced binding may result from increased stability of the AHR LBD and/or AHR
protein complex. Given our recent results indicating that one of the binding sites of the AHR
chaperone protein hsp90 is contained within the AHR LBD (21), one can envision that
increased binding and/or stability of hsp90 within the LBD could further stabilize the AHR,
leading to decreased inactivation of AHR ligand binding activity and consequently an
increase in the overall amount of [3H]TCDD specific binding. Whether these mutations
result in an increase in AHR ligand binding affinity and/or an increase in functional AHRs
that can bind ligand remains to be determined. However the stabilizing effects of Y296H
and T386A mutations on [3H]TCDD specific binding are consistent with their predicted
effect of opening up the ligand binding cavity. Overall, the mutagenesis data confirm the
predictions made from comparative analysis of LBD models of the zebrafish AHRs and
demonstrate experimentally the importance of amino acids at positions 296 and 386 in
facilitating TCDD binding.
The above results demonstrate that insertion of two mutations (Y296H and T386A) can
restore ligand binding to the zfAHR1a; however, these analyses do not determine whether
these mutations also restore the ability of the zfAHR1a to undergo the ligand-dependent
events necessary for AHR transformation and binding to DRE-containing DNA.
Accordingly, wild type and mutant zfAHRs were incubated in the absence or presence of 20
nM TCDD and their ability to transform and bind to DNA was determined by gel retardation
analysis (Figure 5A). Similar to the ligand binding results described above, TCDD-
dependent transformation and DNA binding was observed with zfAHR1a containing the
Y296H/T386A double mutation as well as that containing the Y296H/T386A/H338Q triple
mutation, with DNA binding by the triple mutant zfAHR1a lower than that of the double
mutant. A small but significant increase in TCDD-dependent DNA binding was observed
with zfAHR1a containing the Y296H mutation, but not that with T386A or H388Q. Overall,
these results suggest that even though partial restoration of ligand binding occurs (~50%)
with zfAHR1a containing the Y296H or T386A mutations, the ligand-dependent change in
the AHR necessary to stimulate AHR transformation and ARNT dimerization fails to occur.
Further studies of these mutations may provide insights into the mechanisms by which
ligand binding triggers AHR activation. Interestingly, while the levels of both constitutive
and TCDD-inducible DNA binding by zfAHR1b were dramatically higher than those of
zfAHR2 or zfAHR1a containing the double mutation, quantitatively, the amounts of the
TCDD-dependent enhancement of DNA binding by zfAHR2 and zfAHR1b were similar
(Figure 5B). The reason for the increased constitutive DNA binding by the zfAHR1b/
zfARNT1c complex is not clear. Interestingly, these DNA binding analysis also revealed for
the first time that zfAhR1b:ARNT:DRE complexes can migrate significantly faster in native
PAGE gels than complexes formed with AhR2 or the functional AhR1a mutants (Figure
5A). The reasons for these differences in migration remain to be determined. However, it is
very likely that the significant differences in the overall size and charge of each of the
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zfAhRs (zfAhR2 is 1027 aa with a calculated pI of 7.3, zfAhR1b is 940 aa with a calculated
pI of 6.35 and the mut_zfAhR1a is 787 aa with a calculated pI of 8.05), their relatively low
amino acid homology (~40%) (28,29), differences in the overall protein conformation/
structure of each zfAhR and ultimately their respective zfAhR:ARNT:DRE complexes
would be contributing factors. Overall, the site-directed mutagenesis results reveal that the
mutations that can fully restore ligand (TCDD) binding activity can also restore TCDD-
dependent transformation and DNA binding. These results also demonstrate that the
dimerization and DNA binding interfaces of zfAHR1a appear functional and the apparent
lack of TCDD-dependent zfAHR1a activation likely results, at least in part, from impaired
TCDD binding as a result of selected substitutions within its LBD.
The inability of zfAHR1a to bind TCDD or mediate TCDD-dependent gene expression or
toxicity in vivo led to the suggestion that it may be an AHR pseudogene instead of a
functional AHR gene (29). Not only does zfAHR1a have an altered LBD that fails to bind
TCDD, but previous domain swapping experiments between zfAHR1a and zfAHR2
suggested that the zfAHR1a transactivation domain was also nonfunctional as it failed to
confer TCDD-dependent gene expression in transfection experiments when fused to the N-
terminal end of zfAHR2 containing functional ligand binding, DNA binding and
dimerization domains (28). However, the functional activity of this transactivation domain
may be zfAHR1a-specific and may require it to have a functional LBD. Accordingly, to test
this, we examined TCDD-dependent transcriptional activity of wild-type and mutant
zfAHR1a in COS-7 cells transiently co-transfected with the AhR-responsive luciferase
reporter plasmid pGudLuc6.1. While TCDD induced luciferase activity in cells transfected
with wild-type zfAHR1b or zfAHR2, no TCDD-induction was observed in cells
cotransfected with wild-type or mutant zfAHR1a, irrespective of its ability to bind TCDD or
exhibit TCDD-dependent DNA binding (Figure 6). Together, these results extend previous
studies demonstrating that the zfAHR1a transactivation domain is nonfunctional, by
demonstrating that even changes that dramatically restore ligand binding and DNA binding
in a native context (i.e. not a chimeric protein) are insufficient to restore ligand-dependent
transactivation function of this AHR.
Given the dramatic structural diversity of AHR ligands, combined with recent evidence of
differential binding of such structurally diverse ligands with different residues within the
AHR ligand binding cavity (3,11-14), it is possible that while zfAHR1a is unable to bind
TCDD-like chemicals, it may still bind and be activated by chemicals that are structurally
distinct from TCDD. In fact, molecular docking studies using the AHR LBD homology
model identified leflunomide as a possible unique ligand for zfAHR1a (64). In addition,
analysis in transgenic zebrafish in which the various zfAHRs had been knocked out or
knocked down revealed that leflunomide could induce CYP1A expression in a zfAHR1a-
dependent manner (64). These studies suggested that although leflunomide was predicted to
bind differently within the LBDs of zfAHR1a and zfAHR2, it was still able to stimulate the
same gene induction response and thus must contact common key residues critical for
activation of AHR transformation events. Other studies also suggest that zfAHR1a may be
functional with certain ligands; Incardona and co-workers have reported that knock-down of
zfAHR1a provides protection against the embryotoxicity of pyrene (65). These results not
only indicate that the transactivation domain of zfAHR1a is functional, but that its activation
appears to occur by a ligand-selective mechanism that is distinct from that of the zfAHR2
transactivation domain. How zfAHR1a is activated by leflunomide and whether other AHR
ligands can also bind and activate this AHR remain to be elucidated.
Overall, our findings demonstrate that direct comparison of homology models of AHR
LBDs from different species is able to reveal the evolutionary conservation of some key
features in the binding cavities of AHRs with high TCDD binding affinity. Moreover, our
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experimental results verify the ability of the modeling approach to predict the specific
residues that play a critical role in TCDD binding. More generally, the results of this study
indicate that comparative analysis of homology models can provide important structural
insights into ligand-specific mechanisms of AHR binding and activation that may help to
explain some of the dramatic ligand- and species-specific differences in AHR function. Such
a mechanistic understanding will inform efforts to explore the AHR as a target for
therapeutic intervention and to use the AHR as a molecular biomarker of susceptibility in
risk assessment.
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ABBREVIATIONS
AHR Aryl Hydrocarbon Receptor
mAHR Mus Musculus (mouse) Aryl Hydrocarbon Receptor
zfAHR Danio rerio (zebrafish) Aryl Hydrocarbon Receptor; all other AHR species
abbreviations are presented in Table 1
ARNT Aryl Hydrocarbon Receptor Nuclear Translocator
bHLH Basic Helix-Loop-Helix
DMSO Dimethyl Sulfoxide
DMEM Dulbecco©s Minimal Essential Medium
DRE Dioxin Responsive Element
HAHs Halogenated Aromatic Hydrocarbons
HIF-2a Hypoxia-Inducible Factor 2α
LBD Ligand Binding Domain
MEDG 25 mM MOPS-NaOH pH 7.5, 1 mM EDTA, 1 mM DTT, 10% glycerol
NMR Nuclear Magnetic Resonance
PAS Per-ARNT-Sim
PDB Protein Data Bank
RMSD Root Mean Square Distance
TCDD 2,3,7,8-Tetrachlorodibenzo-p-dioxin
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FIGURE 1.
Cartoon representation of the homology models of three AHR LBDs with high affinity for
TCDD, representative in each class. In the upper part, mouse, chicken and zebrafish AHR
(mAHR, chAHR, zfAHR2) cartoons are colored according to the Secondary Structure
attribution obtained by DSSPcont (45) (red: helices, yellow: β-strands). The secondary
structure elements of the mAHR are labeled according to the nomenclature generally
adopted for the PAS structures. In the lower part, cartoons are colored in grey, and the
molecular surfaces that include the consensus cavity of the high affinity mammalian AHRs
(cyan), the chAHR (green) and the zfAHR2 (orange) cavities are shown. Representation of
the cavity surfaces was produced with PyMOL (47).
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FIGURE 2.
Ligand binding cavities of mammalian and avian AHRs. A. Sequence alignment of selected
mammalian and avian AHRs. Except for the mAHR (taken as reference), only the residues
identified by the CastP server (48) as internal to the binding cavities are shown. Internal
residues conserved in all mammalian AHRs with high affinity for TCDD are indicated by
asterisks. B. Cartoon representation of the modeled mAHR LBD. The internal residues
conserved in all high affinity mammalian AHRs are shown as grey sticks and the residues
that are not conserved in mammalian and avian AHRs with medium or low TCDD affinity
are labeled and shown as red sticks. The molecular surface of the consensus cavity for
mammalian AHRs is shown in cyan. C. Stick representation of the mAHR (cyan),
mDBAAHR (yellow) and huAHR (pink) residues in the ªTCDD binding fingerprintº
positions (18). Steric hindrance of unconserved residues is shown as van der Waals spheres
around the side chains. D. Stick representation of the residues of the avian AHRs (chAHR in
green and tAHR in magenta) in the TCDD binding fingerprint positions, compared to those
of mAHR (cyan). Van der Waals spheres are shown around the side chains of unconserved
residues.
Fraccalvieri et al. Page 17
Biochemistry. Author manuscript; available in PMC 2014 January 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 3.
Ligand binding cavities of fish AHRs. A. Sequence alignment of zfAHR2, zfAHR1b and
zfAHR1a. Except for the zfAHR2 (taken as reference), only the residues identified by the
CastP server (48) as internal to the binding cavities are shown. B. Cartoon representation of
the modeled zfAHR2 LBD. The internal residues are shown as grey sticks and the residues
that are different in the zfAHR1a (lacks TCDD binding) are labeled and shown as black
sticks. The molecular surface of the internal cavity is shown in orange. C. Cartoon
representation of the modeled zfAHR1b LBD. The internal residues are shown as grey sticks
and the residues that are different in zfAHR1a are labeled and shown as black sticks. The
molecular surface of the internal cavity is shown in red. D. Cartoon representation of the
modeled zfAHR1a LBD. The internal residues are shown as grey sticks and residues that are
different with respect to the zfAHRs that bind TCDD are labeled and shown as black sticks.
The molecular surface of the truncated zfAHR1a cavity is shown in blue. E. The steric
hindrance of Tyr296, Thr386 and His388 of zfAHR1a (shown as blue Van der Waals
spheres) results in truncated internal cavity (blue). The corresponding residues in the high
affinity TCDD-binding zfAHR2 are shown in orange.
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FIGURE 4.
[3H]TCDD specific binding to wild-type zebrafish AHR1a, AHR1b and AHR1a containing
various mutations. Wild-type and mutant zfAHRs were synthesized in vitro and subjected to
[3H]TCDD ligand binding analysis by sucrose density centrifugation as described under
Methods. Specific binding is expressed as a percentage of the specific binding to AHR1b,
measured in the same experiment. Top panel shows results compiled from three
experiments, with 2 or 3 replicate samples analyzed for each AHR. Bottom panels show
representative results from one of the experiments in which all AHRs were analyzed. Note
the difference in scale on the two panels.
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FIGURE 5.
Effect of site-directed mutagenesis of AHR1a on its ability to transform and bind to DNA in
a TCDD-inducible manner. A. Wild-type zfAHR2, zfAHR1b, and zfAHR1a containing
various mutations were synthesized in vitro, incubated in the presence of DMSO (D) or 20
nM TCDD (T) and transformation and DNA binding assessed by gel retardation analysis as
described under Methods. B. Constitutive and inducible protein-DNA complexes in the
dried gel were quantitated using a Fujifilm FLA9000 imager with Multi Gauge software and
values represent the mean  SD of triplicate binding reactions. A typical gel retardation
analysis is shown.
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FIGURE 6.
Effect of site-directed mutagenesis of AHR1a on its ability to activate transcription. COS-7
cells were transfected with expression constructs for the zebrafish ARNT2b (25 ng),
pGudLuc6.1 (20 ng), pGL4.74 (transfection control), and the indicated AHR expression
constructs (5 ng). ªNo AHRº indicates transfection with only the reporter construct and the
transfection control. The cells were exposed to dimethyl sulfoxide or TCDD (10 nM). The
luciferase activity was measured in a luminometer and the relative luciferase units were
calculated by normalizing the firefly luciferase activity to the transfection control Renilla
luciferase.
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